<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Therap Adv Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Therap Adv Gastroenterol</journal-id><journal-id journal-id-type="pmc-domain-id">1352</journal-id><journal-id journal-id-type="pmc-domain">tag</journal-id><journal-id journal-id-type="publisher-id">TAG</journal-id><journal-title-group><journal-title>Therapeutic Advances in Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1756-283X</issn><issn pub-type="epub">1756-2848</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10392190</article-id><article-id pub-id-type="pmcid-ver">PMC10392190.1</article-id><article-id pub-id-type="pmcaid">10392190</article-id><article-id pub-id-type="pmcaiid">10392190</article-id><article-id pub-id-type="pmid">37533708</article-id><article-id pub-id-type="doi">10.1177/17562848231188587</article-id><article-id pub-id-type="publisher-id">10.1177_17562848231188587</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Middle small-bowel segment Lewis score may predict long-term outcomes among patients with quiescent Crohn&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8601-6550</contrib-id><name name-style="western"><surname>Ukashi</surname><given-names initials="O">Offir</given-names></name><xref rid="corresp1-17562848231188587" ref-type="corresp"/><aff id="aff1-17562848231188587">Gastroenterology Institute and Internal Medicine Department A, Sheba Medical Center, Tel HaShomer, Ha&#8217;ela 1, Ramat Gan 52621, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6191-9270</contrib-id><name name-style="western"><surname>Yablecovitch</surname><given-names initials="D">Doron</given-names></name><aff id="aff2-17562848231188587">Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1513-7280</contrib-id><name name-style="western"><surname>Lahat</surname><given-names initials="A">Adi</given-names></name><aff id="aff3-17562848231188587">Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Selinger</surname><given-names initials="L">Limor</given-names></name><aff id="aff4-17562848231188587">Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neuman</surname><given-names initials="S">Sandra</given-names></name><aff id="aff5-17562848231188587">Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eliakim</surname><given-names initials="R">Rami</given-names></name><aff id="aff6-17562848231188587">Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ben-Horin</surname><given-names initials="S">Shomron</given-names></name><aff id="aff7-17562848231188587">Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7156-0588</contrib-id><name name-style="western"><surname>Kopylov</surname><given-names initials="U">Uri</given-names></name><xref rid="corresp2-17562848231188587" ref-type="corresp"/><aff id="aff8-17562848231188587">Gastroenterology Institute, Sheba Medical Center, Tel HaShomer, Ha&#8217;ela 1, Ramat Gan 52621, Israel</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib></contrib-group><author-notes><corresp id="corresp1-17562848231188587"><email>offirukashi@gmail.com</email></corresp><corresp id="corresp2-17562848231188587"><email>ukopylov@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">426298</issue-id><elocation-id>17562848231188587</elocation-id><history><date date-type="received"><day>13</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-03 11:25:24.500"><day>03</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_17562848231188587.pdf"/><abstract><sec id="section1-17562848231188587"><title>Background:</title><p>Video capsule endoscopy (VCE) has been proven to accurately diagnose small-bowel inflammation and predict flares among patients with quiescent Crohn&#8217;s disease (CD). However, data regarding its predictive role in this population over an extended follow-up are scarce.</p></sec><sec id="section2-17562848231188587"><title>Objectives:</title><p>To predict clinical exacerbation and to assess the yield of Lewis score in identifying CD patients with future clinical exacerbation during an extended follow-up (&gt;24&#8201;months).</p></sec><sec id="section3-17562848231188587"><title>Design:</title><p>A <italic toggle="yes">post hoc</italic> analysis study.</p></sec><sec id="section4-17562848231188587"><title>Methods:</title><p>Adult patients with quiescent small-bowel CD who were followed with VCE, inflammatory biomarkers and magnetic resonance enterography in a prospective study (between 2013 and 2018). We extracted extended clinical data (up to April 2022). The primary composite outcome (i.e. clinical exacerbation) was defined as intestinal surgery, endoscopic dilation, CD-related admission, corticosteroid administration, or biological/immunomodulator treatment change during follow-up.</p></sec><sec id="section5-17562848231188587"><title>Results:</title><p>Of the 61 patients in the study [median age 29 (24&#8211;37) years, male 57.4%, biologic treatment 46.7%], 18 patients met the primary outcome during an extended follow-up [median 58.0 (34.5&#8211;93.0) months]. On univariable analysis, complicated [hazard ratio (HR) 7.348, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002] and stricturing disease phenotype (HR 5.305, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001) were associated with higher risk for clinical exacerbation during follow-up. A baseline VCE middle small-bowel segment Lewis score (midLS)&#8201;&#10878;&#8201;135 identified patients with future exacerbation [AUC (area under the curve) 0.767, 95% confidence interval (CI) 0.633&#8211;0.902, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001, HR 6.317, 93% negative predictive value], whereas the AUC of the conventional Lewis score was 0.734 (95% CI: 0.589&#8211;0.879, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004). Sensitivity analysis restricted to patients with either complicated (<italic toggle="yes">n</italic>&#8201;=&#8201;34) or stricturing (<italic toggle="yes">n</italic>&#8201;=&#8201;26) disease phenotype revealed that midLS still predicted clinical exacerbation during follow-up (AUC 0.747/0.753, respectively), in these patients.</p></sec><sec id="section6-17562848231188587"><title>Conclusion:</title><p>MidLS predicts treatment failure in quiescent CD patients (median follow-up of 5&#8201;years) independently of disease phenotype.</p></sec></abstract><kwd-group><kwd>Crohn&#8217;s disease</kwd><kwd>Lewis score</kwd><kwd>MidLS</kwd><kwd>video capsule endoscopy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2023</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section7-17562848231188587"><title>Introduction</title><p>Crohn&#8217;s disease (CD) is a state of chronic, relapsing, and remitting intestinal inflammation, which over time can lead to tissue detriments such as strictures, fistulas, and abscesses.<sup><xref rid="bibr1-17562848231188587" ref-type="bibr">1</xref>,<xref rid="bibr2-17562848231188587" ref-type="bibr">2</xref></sup> Mucosal healing and clinical remission (i.e. deep remission) were proven as beneficial objectives, which are associated with improved disease course and prevention of poor clinical outcomes and future complications in patients with CD.<sup><xref rid="bibr3-17562848231188587" ref-type="bibr">3</xref><xref rid="bibr4-17562848231188587" ref-type="bibr"/>&#8211;<xref rid="bibr5-17562848231188587" ref-type="bibr">5</xref></sup></p><p>There is no reference standard for disease monitoring of patients with CD.<sup>
<xref rid="bibr6-17562848231188587" ref-type="bibr">6</xref>
</sup> Inflammatory biomarkers (e.g. C-reactive protein and fecal calprotectin) are recommended as intermediate medium-term tests<sup><xref rid="bibr4-17562848231188587" ref-type="bibr">4</xref>,<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref></sup> to monitor inflammation in CD,<sup><xref rid="bibr1-17562848231188587" ref-type="bibr">1</xref>,<xref rid="bibr6-17562848231188587" ref-type="bibr">6</xref></sup> although no mucosal visualization is provided. On the other hand, strict monitoring of mucosal inflammation requires invasive (e.g. ileocolonoscopy) and costly [e.g. magnetic resonance enterography (MRE)] procedures, and its prediction yield is still incomplete.<sup>
<xref rid="bibr8-17562848231188587" ref-type="bibr">8</xref>
</sup></p><p>Video capsule endoscopy (VCE) affords a noninvasive visualization of the mucosal surface of the entire small bowel.<sup>
<xref rid="bibr9-17562848231188587" ref-type="bibr">9</xref>
</sup> Its use is endorsed in newly diagnosed patients with CD by both American<sup>
<xref rid="bibr1-17562848231188587" ref-type="bibr">1</xref>
</sup> and European<sup>
<xref rid="bibr6-17562848231188587" ref-type="bibr">6</xref>
</sup> guidelines. Small-bowel VCE scores (i.e. Niv and Lewis scores) were proven to accurately predict future clinical outcomes among patients with CD,<sup><xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>,<xref rid="bibr10-17562848231188587" ref-type="bibr">10</xref>,<xref rid="bibr11-17562848231188587" ref-type="bibr">11</xref></sup> and some of the studies have even delineated distinctive Lewis score thresholds which were associated with worse future clinical outcomes.<sup><xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>,<xref rid="bibr10-17562848231188587" ref-type="bibr">10</xref></sup> However, data regarding the yield of small-bowel VCE scores during an extended follow-up (&gt;24&#8201;months) are lacking, and definitive recommendations to use it have not yet been implemented in the existing guidelines.</p><p>In this study, we aimed to predict worse clinical outcomes among patients with quiescent CD over an extended follow-up (&gt;24&#8201;months). We also aimed to assess Lewis score yield in identifying patients with future clinical exacerbation during the extended follow-up, as we demonstrated for the shorter follow-up (up to 24&#8201;months).<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup></p></sec><sec sec-type="materials|methods" id="section8-17562848231188587"><title>Materials and methods</title><sec id="section9-17562848231188587"><title>Study design and population</title><p>This was a <italic toggle="yes">post hoc</italic> analysis of adult patients (&#10878;18&#8201;years old) with quiescent ileal or ileocolonic CD (L1 or L3) who were enrolled between 2013 and 2015, and followed with clinic visits, inflammatory biomarkers, MRE and VCE (SB-III and PillCam colon capsule; Given Imaging, Yoqneam, Israel) as part of previously published prospective study.<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup></p><p>Eligibility criteria included the following: Crohn&#8217;s disease activity index (CDAI)&#8201;&#10877;&#8201;150 or mild symptoms (CDAI&#8201;&#10877;&#8201;220) in 3&#8211;24&#8201;months prior to inclusion, and the absence of corticosteroid use and/or medication change in the parallel period. Only patients with proven small-bowel patency, as tested by patency capsule (PC) ingestion [i.e. intact PC passage through the small bowel within 30&#8201;h (Given Imaging, Yoqneam, Israel)],<sup>
<xref rid="bibr12-17562848231188587" ref-type="bibr">12</xref>
</sup> were included.</p></sec><sec id="section10-17562848231188587"><title>Study outcomes</title><p>The primary composite outcome was a clinical exacerbation defined as intestinal surgery, endoscopic dilation, CD-related admission, need for corticosteroids, or biological/immunomodulator treatment initiation or change during the follow-up (excluding cases of dose intensification). We aimed to identify predictors for the predefined clinical exacerbation over an extended follow-up.</p></sec><sec id="section11-17562848231188587"><title>Data extraction and definitions</title><p>The following baseline clinical and laboratory data were extracted<sup>
<xref rid="bibr13-17562848231188587" ref-type="bibr">13</xref>
</sup> the case report forms (CRFs) of the previously published study<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup>: clinicodemographic parameters such as age, sex, body mass index (kg/m<sup>2</sup>), smoking status, disease duration, age at disease initiation, involved bowel segments, the presence of perianal disease, extraintestinal manifestations, the presence of complicated disease phenotype (stricturing and/or penetrating), past disease-related hospitalization, past disease-related abdominal operation, past use of corticosteroids, biologics at baseline, C-reactive protein (mL/L) and fecal-calprotectin (&#181;g/g) levels, and baseline MRE scoring to evaluate small-bowel inflammatory activity and damage [Lemann, Magnetic Resonance Index of Activity (MaRIA), and Clermont scores<sup><xref rid="bibr14-17562848231188587" ref-type="bibr">14</xref>&#8211;<xref rid="bibr16-17562848231188587" ref-type="bibr">16</xref></sup>]. Mucosal inflammation was quantified for each of the small-bowel tertiles (equally divided based on the capsule transit time), using the Lewis score system.<sup>
<xref rid="bibr17-17562848231188587" ref-type="bibr">17</xref>
</sup> Conventional Lewis score (convLS) was then determined, based on the highest score of the three tertiles.<sup>
<xref rid="bibr17-17562848231188587" ref-type="bibr">17</xref>
</sup></p><p>Data regarding the study outcomes were gathered<sup>
<xref rid="bibr13-17562848231188587" ref-type="bibr">13</xref>
</sup> based on the electronic medical records. To attenuate the effect of missing data, we conducted a phone call to each patient with a lack of an appropriate clinical follow-up, to complete data gathering, in regard to the composite outcome.</p></sec><sec id="section12-17562848231188587"><title>Statistical analysis</title><p>Discrete variables were presented as proportions. Continuous variables were assessed for normal distribution by Shapiro&#8211;Wilk test and expressed as median [interquartile range (IQR)] or as mean&#8201;&#177;&#8201;standard deviation, appropriately. Patients with and without clinical exacerbation were compared using two-sample <italic toggle="yes">t</italic>-test or Mann&#8211;Whitney <italic toggle="yes">U</italic> test for the continuous variables, while &#967;<sup>2</sup> test with Yates correction was used for the discrete ones. We defined follow-up duration as the time elapsed since enrollment to the last available follow-up of each patient.<sup>
<xref rid="bibr13-17562848231188587" ref-type="bibr">13</xref>
</sup></p><p>Survival analysis for clinical exacerbation (i.e. the primary composite outcome) was conducted using Kaplan&#8211;Meier curves with log-rank test calculation. Univariable analysis regarding the primary composite outcome was performed using cox proportional hazard ratio [HR; 95% confidence interval (CI)] and log-rank test for continuous and categorical variables, respectively. Log-minus-log and multicollinearity estimation were used to evaluate the Cox P-H assumptions.</p><p>A receiver operating characteristic (ROC) curve was constructed and area under the curve (AUC) was calculated for diagnostic tests with continuous results. Youden most accurate points were computed for each ROC curve, as well as for sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV).<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup></p><p>All statistical tests were two-sided and <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was considered as statistically significant. Statistical analyses (including survival graphs) were performed using SPSS software (IBM SPSS statistics for windows, version 26; IBM corp. Armonk, NY, USA, 2019).</p></sec></sec><sec sec-type="results" id="section13-17562848231188587"><title>Results</title><p>Out of 90 patients who were screened with PC and MRE for small-bowel patency, 29 patients were excluded (17 patients due to retained PC, 6 patients withdrew consent, 3 patients due to clinical flare, 2 patients due to treatment escalation following MRE findings, and 1 patient due to technical reason); thus, 61 were enrolled between 2013 and 2015 (<xref rid="fig1-17562848231188587" ref-type="fig">Figure 1</xref>) and underwent VCE procedure.</p><fig position="float" id="fig1-17562848231188587" orientation="portrait"><label>Figure 1.</label><caption><p>Study flowchart.</p><p>CD, Crohn&#8217;s disease; MRE, magnetic resonance enterography; PC, patency capsule.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17562848231188587-fig1.jpg"/></fig><p>Overall, 18 patients met the primary composite outcome (29.5%) during the study follow-up [median of 58.0 (IQR: 34.5&#8211;93.0) months]. One patient underwent endoscopic dilation (1.6%), 6 patients were hospitalized due to CD clinical flare (10%), 7 patients needed a corticosteroid treatment (11%), and 16 patients had their treatment been modified with biologics/immunomodulators (26%). There was not any case of CD-related surgery during the study follow-up. The median time to clinical exacerbation (i.e., the primary composite outcome) among these patients was 32.5 (IQR: 9.75&#8211;62.25) months. There was no case of VCE retention or any obstructive complication in any of the 61 VCE procedures.</p><p>Patients&#8217; baseline characteristics are presented in <xref rid="table1-17562848231188587" ref-type="table">Table 1</xref>. Demographics were overall comparable between patients with and without clinical exacerbation: median age of 32 (IQR: 21&#8211;44) years <italic toggle="yes">versus</italic> 29 (IQR: 26&#8211;36), respectively (<italic toggle="yes">p</italic>&#8201;=&#8201;0.537), and male gender proportion of 72.2% <italic toggle="yes">versus</italic> 51.2%, respectively (<italic toggle="yes">p</italic>&#8201;=&#8201;0.129). Most of the patients had a baseline CDAI score of &#10877;150 [16/18 (88.9%) <italic toggle="yes">versus</italic> 38/43 (88.4%) of the patients with and without clinical exacerbation during follow-up, respectively (<italic toggle="yes">p</italic>&#8201;=&#8201;1.000)]. The rest of the patients had a baseline CDAI score of 151&#8211;220 [2/18 (11.1%) <italic toggle="yes">versus</italic> 5/43 (11.6%), respectively]. Baseline disease-related features were quite balanced between both groups, except for higher rate of complicated disease phenotype among patients with clinical exacerbation compared with the controls (89% <italic toggle="yes">versus</italic> 43%, respectively, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002). Biologics use was less prevalent among patients with clinical exacerbation compared with the controls (22.2% <italic toggle="yes">versus</italic> 57.1%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.013).</p><table-wrap position="float" id="table1-17562848231188587" orientation="portrait"><label>Table 1.</label><caption><p>Baseline characteristics of patients with and without clinical exacerbation during follow-up.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17562848231188587-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Patients with clinical exacerbation (<italic toggle="yes">n</italic>&#8201;=&#8201;18)</th><th align="left" rowspan="1" colspan="1">Patients without clinical exacerbation (<italic toggle="yes">n</italic>&#8201;=&#8201;43)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Demographics</td></tr><tr><td rowspan="1" colspan="1">&#8195;Age (years)</td><td rowspan="1" colspan="1">32 (21&#8211;44)</td><td rowspan="1" colspan="1">29 (26&#8211;36)</td><td rowspan="1" colspan="1">0.537</td></tr><tr><td colspan="4" rowspan="1">Gender</td></tr><tr><td rowspan="1" colspan="1">&#8195;Male <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">13 (72.2%)</td><td rowspan="1" colspan="1">22 (51.2%)</td><td rowspan="1" colspan="1">0.129</td></tr><tr><td rowspan="1" colspan="1">&#8195;Body mass index (kg/m<sup>2</sup>)<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">24.2 (21.5&#8211;25.3)</td><td rowspan="1" colspan="1">22.1 (21.0&#8211;27.9)</td><td rowspan="1" colspan="1">0.885</td></tr><tr><td rowspan="1" colspan="1">&#8195;Current smoking <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">5 (27.8%)</td><td rowspan="1" colspan="1">7 (16.3%)</td><td rowspan="1" colspan="1">0.498</td></tr><tr><td colspan="4" rowspan="1">Disease-related features</td></tr><tr><td rowspan="1" colspan="1">&#8195;Disease duration (years)<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">3.5 (2&#8211;11)</td><td rowspan="1" colspan="1">4.5 (1.5&#8211;8.5)</td><td rowspan="1" colspan="1">0.571</td></tr><tr><td rowspan="1" colspan="1">&#8195;Age at diagnosis<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">20.0 (35.5&#8211;56.8)</td><td rowspan="1" colspan="1">25.0 (30.5&#8211;42.2)</td><td rowspan="1" colspan="1">0.188</td></tr><tr><td rowspan="1" colspan="1">&#8195;Colonic involvement <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">11 (61.1%)</td><td rowspan="1" colspan="1">22 (52.4%)</td><td rowspan="1" colspan="1">0.533</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proximal small bowel involvement <italic toggle="yes">n</italic> (%)<sup>^,<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref></sup></td><td rowspan="1" colspan="1">1 (5.6%)</td><td rowspan="1" colspan="1">4 (9.5%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;Perianal involvement <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn7-17562848231188587" ref-type="table-fn">&#8225;&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">3 (16.7%)</td><td rowspan="1" colspan="1">11 (26.8%)</td><td rowspan="1" colspan="1">0.608</td></tr><tr><td colspan="4" rowspan="1">Disease behavior</td></tr><tr><td rowspan="1" colspan="1">&#8195;Complicated disease phenotype<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">16 (88.9%)</td><td rowspan="1" colspan="1">18 (42.9%)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;B2 stricturing <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">12 (66.7%)</td><td rowspan="1" colspan="1">11 (26.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;B3 Penetrating <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">2 (11.1%)</td><td rowspan="1" colspan="1">6 (14.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;B2 and B3 phenotype <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn5-17562848231188587" ref-type="table-fn">#</xref>
</sup></td><td rowspan="1" colspan="1">2 (11.1%)</td><td rowspan="1" colspan="1">1 (2.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Extraintestinal manifestations <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn8-17562848231188587" ref-type="table-fn">&#8225;&#8225;&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">4 (22.2%)</td><td rowspan="1" colspan="1">13 (32.5%)</td><td rowspan="1" colspan="1">0.426</td></tr><tr><td rowspan="1" colspan="1">&#8195;Previous hospitalization <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn8-17562848231188587" ref-type="table-fn">&#8225;&#8225;&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">9 (50.0%)</td><td rowspan="1" colspan="1">21 (52.5%)</td><td rowspan="1" colspan="1">0.860</td></tr><tr><td rowspan="1" colspan="1">&#8195;Previous CD surgeries <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">5 (27.8%)</td><td rowspan="1" colspan="1">7 (16.7%)</td><td rowspan="1" colspan="1">0.526</td></tr><tr><td rowspan="1" colspan="1">&#8195;Previous use of corticosteroids <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn7-17562848231188587" ref-type="table-fn">&#8225;&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">16 (94.1%)</td><td rowspan="1" colspan="1">28 (66.7%)</td><td rowspan="1" colspan="1">0.062</td></tr><tr><td rowspan="1" colspan="1">&#8195;Current use of biologics <italic toggle="yes">n</italic> (%)<sup>
<xref rid="table-fn3-17562848231188587" ref-type="table-fn">&#8225;</xref>
</sup></td><td rowspan="1" colspan="1">4 (22.2%)</td><td rowspan="1" colspan="1">24 (57.1%)</td><td rowspan="1" colspan="1">0.013</td></tr><tr><td colspan="4" rowspan="1">Baseline disease measures</td></tr><tr><td rowspan="1" colspan="1">&#8195;CDAI score &#10877;150 <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">16 (88.9%)</td><td rowspan="1" colspan="1">38 (88.4%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;CDAI score &#10877;220 <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">18 (100%)</td><td rowspan="1" colspan="1">43 (100%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;C-reactive protein (mg/L)</td><td rowspan="1" colspan="1">3.95 (1.31&#8211;7.19)</td><td rowspan="1" colspan="1">1.75 (0.51&#8211;4.62)</td><td rowspan="1" colspan="1">0.038</td></tr><tr><td rowspan="1" colspan="1">&#8195;Calprotectin (&#181;g/g)</td><td rowspan="1" colspan="1">149 (44&#8211;300)</td><td rowspan="1" colspan="1">77 (30&#8211;157)</td><td rowspan="1" colspan="1">0.124</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proximal small-bowel LS</td><td rowspan="1" colspan="1">225 (0&#8211;346)</td><td rowspan="1" colspan="1">135 (0&#8211;225)</td><td rowspan="1" colspan="1">0.053</td></tr><tr><td rowspan="1" colspan="1">&#8195;Middle small-bowel LS</td><td rowspan="1" colspan="1">348 (135&#8211;861)</td><td rowspan="1" colspan="1">0 (0&#8211;225)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Distal small-bowel LS</td><td rowspan="1" colspan="1">436 (180&#8211;1061)</td><td rowspan="1" colspan="1">168 (0&#8211;322)</td><td rowspan="1" colspan="1">0.071</td></tr><tr><td rowspan="1" colspan="1">&#8195;Conventional LS<sup>$</sup></td><td rowspan="1" colspan="1">562 (225&#8211;1211)</td><td rowspan="1" colspan="1">225 (135&#8211;374)</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">&#8195;Lemann score</td><td rowspan="1" colspan="1">3.75 (1.06&#8211;13.65)</td><td rowspan="1" colspan="1">1.25 (0.12&#8211;2.81)</td><td rowspan="1" colspan="1">0.018</td></tr><tr><td rowspan="1" colspan="1">&#8195;MaRIA score<sup>
<xref rid="table-fn4-17562848231188587" ref-type="table-fn">&#182;</xref>
</sup></td><td rowspan="1" colspan="1">23.35 (10.01&#8211;32.83)</td><td rowspan="1" colspan="1">13.87 (5.87&#8211;23.32)</td><td rowspan="1" colspan="1">0.044</td></tr><tr><td rowspan="1" colspan="1">&#8195;Clermont score<sup>
<xref rid="table-fn4-17562848231188587" ref-type="table-fn">&#182;</xref>
</sup></td><td rowspan="1" colspan="1">24.78 (10.97&#8211;31.38)</td><td rowspan="1" colspan="1">14.33 (6.55&#8211;25.19)</td><td rowspan="1" colspan="1">0.034</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-17562848231188587"><p><italic toggle="yes">Note</italic>: Continuous variables are presented as median (interquartile range) while categorical ones are presented as proportions (%).</p></fn><fn id="table-fn2-17562848231188587"><label>$</label><p>Conventional Lewis score was defined as the worst segment score</p></fn><fn id="table-fn3-17562848231188587"><label>&#8225;</label><p>Data were missing for one patient.</p></fn><fn id="table-fn4-17562848231188587"><label>&#182;</label><p>Data were missing for nine patients.</p></fn><fn id="table-fn5-17562848231188587"><label>#</label><p>Patients with stenotic and penetrating features.</p></fn><fn id="table-fn6-17562848231188587"><label>^</label><p>Involvement of proximal small bowel which was defined by prior health record documentation.</p></fn><fn id="table-fn7-17562848231188587"><label>&#8225;&#8225;</label><p>Data were missing for two patients.</p></fn><fn id="table-fn8-17562848231188587"><label>&#8225;&#8225;&#8225;</label><p>Data were missing for three patients.</p></fn><fn id="table-fn9-17562848231188587"><p>CD, Crohn&#8217;s disease; CDAI, Crohn&#8217;s disease activity index; LS, Lewis score; MaRIA, Magnetic Resonance Index of Activity.</p></fn></table-wrap-foot></table-wrap><p>Median measures of C-reactive protein, middle small-bowel tertile LS (midLS), and convLS (i.e. worst segment score) and the examined MRE scores were higher among patients with clinical exacerbation compared with the controls. No significant difference was observed regarding the median of fecal-calprotectin levels, and the median Lewis score of the proximal and the distal small-bowel tertiles between both groups (<xref rid="table1-17562848231188587" ref-type="table">Table 1</xref>).</p><p>Three patients out of the 16 patients who had needed a treatment modification during follow-up were on biologics (i.e. adalimumab) at baseline. Methotrexate was added to adalimumab in one patient, while treatment was changed to ustekinumab in the others. Of the rest of the patients whose treatment was changed (<italic toggle="yes">n</italic>&#8201;=&#8201;13), nine patients were on azathioprine/mercaptopurine, four patients had no treatment, and one patient was on 5-aminosalicylic acid at baseline. Among them, infliximab, adalimumab, and vedolizumab were prescribed for seven patients, five patients, and one patient, respectively, during follow-up. The median time to treatment modification during follow-up was 28.5 (10.25&#8211;73.25) months. The median time to steroid prescription (i.e. prednisone or budesonide) during follow-up was 35 (15&#8211;47) months.</p><p>Univariable analyses regarding the primary composite outcome are summarized in <xref rid="table2-17562848231188587" ref-type="table">Table 2</xref>. Complicated (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002) and stricturing disease phenotype (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001) were the only clinicodemographic variables to be associated with higher risk for future clinical exacerbation on univariable analysis. We found fecal-calprotectin level (<italic toggle="yes">p</italic>&#8201;=&#8201;0.027), midLS (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), distal small-bowel tertile Lewis score (<italic toggle="yes">p</italic>&#8201;=&#8201;0.007), convLS (<italic toggle="yes">p</italic>&#8201;=&#8201;0.006), Lemann score (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), MaRIA score (<italic toggle="yes">p</italic>&#8201;=&#8201;0.034), and Clermont score (<italic toggle="yes">p</italic>&#8201;=&#8201;0.033) to be associated with higher risk for clinical exacerbation. Since there were only 18 cases of clinical exacerbation in this cohort study, we did not perform multivariable regression analysis, due to low event-per-variable ratio.</p><table-wrap position="float" id="table2-17562848231188587" orientation="portrait"><label>Table 2.</label><caption><p>Univariable and ROC (receiver operating characteristic) analyses regarding the predefined composite outcome (intestinal surgery, endoscopic dilation, CD-related admission, need for corticosteroids, or biological/immunomodulator treatment change).</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17562848231188587-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="2" rowspan="1">Univariable analysis</th><th align="left" colspan="3" rowspan="1">ROC analysis<xref rid="table-fn10-17562848231188587" ref-type="table-fn">*</xref></th></tr><tr><th align="left" rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="left" rowspan="1" colspan="1">AUC (95% CI)</th><th align="left" rowspan="1" colspan="1">Youden index</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.998 (0.954&#8211;1.045)</td><td rowspan="1" colspan="1">0.947</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2.258 (0.792&#8211;6.434)</td><td rowspan="1" colspan="1">0.118</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Body mass index</td><td rowspan="1" colspan="1">0.972 (0.858&#8211;1.101)</td><td rowspan="1" colspan="1">0.655</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Current smoking</td><td rowspan="1" colspan="1">1.781 (0.634&#8211;5.003)</td><td rowspan="1" colspan="1">0.267</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Disease duration</td><td rowspan="1" colspan="1">1.000 (0.993&#8211;1.008)</td><td rowspan="1" colspan="1">0.927</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age at diagnosis</td><td rowspan="1" colspan="1">0.966 (0.954&#8211;1.041)</td><td rowspan="1" colspan="1">0.869</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Colonic involvement</td><td rowspan="1" colspan="1">1.172 (0.454&#8211;3.025)</td><td rowspan="1" colspan="1">0.743</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Proximal small bowel involvement</td><td rowspan="1" colspan="1">0.674 (0.089&#8211;5.097)</td><td rowspan="1" colspan="1">0.700</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Perianal involvement</td><td rowspan="1" colspan="1">0.808 (0.231&#8211;2.830)</td><td rowspan="1" colspan="1">0.738</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Complicated disease-phenotype</td><td rowspan="1" colspan="1">7.348 (1.688&#8211;31.993)</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Stricturing disease phenotype</td><td rowspan="1" colspan="1">5.305 (1.742&#8211;16.154)</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Penetrating disease phenotype</td><td rowspan="1" colspan="1">1.429 (0.469&#8211;4.357)</td><td rowspan="1" colspan="1">0.528</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Extraintestinal manifestations</td><td rowspan="1" colspan="1">0.430 (0.137&#8211;1.347)</td><td rowspan="1" colspan="1">0.137</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Previous hospitalization</td><td rowspan="1" colspan="1">0.830 (0.328&#8211;2.97)</td><td rowspan="1" colspan="1">0.693</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Previous CD surgeries</td><td rowspan="1" colspan="1">2.011 (0.715&#8211;5.655)</td><td rowspan="1" colspan="1">0.177</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Previous use of systemic corticosteroids</td><td rowspan="1" colspan="1">4.538 (0.595&#8211;34.625)</td><td rowspan="1" colspan="1">0.110</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">C-reactive protein level</td><td rowspan="1" colspan="1">1.023 (0.959&#8211;1.092)</td><td rowspan="1" colspan="1">0.481</td><td rowspan="1" colspan="1">0.669 (0.530&#8211;0.809)</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">0.038</td></tr><tr><td rowspan="1" colspan="1">Calprotectin level</td><td rowspan="1" colspan="1">1.005 (1.000&#8211;1.010)</td><td rowspan="1" colspan="1">0.027</td><td rowspan="1" colspan="1">0.625 (0.458&#8211;0.792)</td><td rowspan="1" colspan="1">188</td><td rowspan="1" colspan="1">0.127</td></tr><tr><td rowspan="1" colspan="1">Proximal small-bowel LS</td><td rowspan="1" colspan="1">1.000 (1.000&#8211;1.001)</td><td rowspan="1" colspan="1">0.157</td><td rowspan="1" colspan="1">0.52 (0.491&#8211;0.814)</td><td rowspan="1" colspan="1">262</td><td rowspan="1" colspan="1">0.062</td></tr><tr><td rowspan="1" colspan="1">Middle small-bowel LS</td><td rowspan="1" colspan="1">1.002 (1.001&#8211;1.003)</td><td rowspan="1" colspan="1">&lt;0.001</td><td rowspan="1" colspan="1">0.767 (0.633&#8211;0.902)</td><td rowspan="1" colspan="1">135</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Distal small-bowel LS</td><td rowspan="1" colspan="1">1.001 (1.000&#8211;1.001)</td><td rowspan="1" colspan="1">0.007</td><td rowspan="1" colspan="1">0.645 (0.488&#8211;0.803)</td><td rowspan="1" colspan="1">510</td><td rowspan="1" colspan="1">0.075</td></tr><tr><td rowspan="1" colspan="1">Conventional LS</td><td rowspan="1" colspan="1">1.001 (1.000&#8211;1.001)</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">0.734 (0.589&#8211;0.879)</td><td rowspan="1" colspan="1">368</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">Lemann score</td><td rowspan="1" colspan="1">1.130 (1.052&#8211;1.214)</td><td rowspan="1" colspan="1">&lt;0.001</td><td rowspan="1" colspan="1">0.693 (0.539&#8211;0.847)</td><td rowspan="1" colspan="1">1.83</td><td rowspan="1" colspan="1">0.018</td></tr><tr><td rowspan="1" colspan="1">MaRIA score</td><td rowspan="1" colspan="1">1.055 (1.002&#8211;1.111)</td><td rowspan="1" colspan="1">0.034</td><td rowspan="1" colspan="1">0.688 (0.520&#8211;0.857)</td><td rowspan="1" colspan="1">26.52</td><td rowspan="1" colspan="1">0.044</td></tr><tr><td rowspan="1" colspan="1">Clermont score</td><td rowspan="1" colspan="1">1.056 (1.003&#8211;1.112)</td><td rowspan="1" colspan="1">0.033</td><td rowspan="1" colspan="1">0.698 (0.540&#8211;0.856)</td><td rowspan="1" colspan="1">7.23</td><td rowspan="1" colspan="1">0.034</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn10-17562848231188587"><label>*</label><p>ROC analysis was performed only for diagnostic test with continuous results.</p></fn><fn id="table-fn11-17562848231188587"><p>AUC, area under the curve; CD, Crohn&#8217;s disease; CI, confidence interval; LS, Lewis score; MaRIA, Magnetic Resonance Index of Activity.</p></fn></table-wrap-foot></table-wrap><p>On ROC curve analysis regarding future clinical exacerbation, baseline midLS had the highest AUC value (0.767, 95% CI: 0.633&#8211;0.902, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001) followed by convLS with AUC value of 0.734 (95% CI: 0.589&#8211;0.879, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004) (<xref rid="table2-17562848231188587" ref-type="table">Table 2</xref>), without statistically significant difference performing AUCs comparison. MidLS&#8201;&#10878;&#8201;135 was the best threshold to identify patients with higher probability for clinical exacerbation (HR 6.317, 95% CI: 1.820&#8211;21.922) with a sensitivity, specificity, PPV, and NPV of 86%, 73%, 53%, and 93%, respectively (<xref rid="fig2-17562848231188587" ref-type="fig">Figure 2</xref>). The ideal cutoff of convLS was &#10878;368 with a sensitivity, specificity, PPV, and NPV of 75%, 80%, 62%, and 88%, respectively.</p><fig position="float" id="fig2-17562848231188587" orientation="portrait"><label>Figure 2.</label><caption><p>Kaplan&#8211;Meier graph of survival without the predefined composite outcome (intestinal surgery, endoscopic dilation, CD-related admission, need for corticosteroids, or biological/immunomodulator treatment change) among the entire cohort population, divided to patients with and without middle small-bowel segment Lewis score (midLS)&#8201;&#10878;&#8201;135.</p><p>CD, Crohn&#8217;s disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17562848231188587-fig2.jpg"/></fig><p>Even among patients with either complicated (<italic toggle="yes">n</italic>&#8201;=&#8201;34) or stricturing disease phenotype (<italic toggle="yes">n</italic>&#8201;=&#8201;26), midLS (<xref rid="fig3-17562848231188587" ref-type="fig">Figures 3</xref> and <xref rid="fig4-17562848231188587" ref-type="fig">4</xref>) and convLS still identified patients with higher risk of clinical exacerbation. Although no significant difference was observed, convLS tended to better predict future clinical exacerbation compared with the midLS among patients with complicated disease phenotype [AUC 0.783 (95% CI: 0.624&#8211;0.942, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005) <italic toggle="yes">versus</italic> 0.747 (95% CI: 0.578&#8211;0.915, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014)]. The best thresholds were convLS&#8201;&#10878;&#8201;195 (HR 8.800, 95% CI: 1.153&#8211;67.172) and midLS&#8201;&#10878;&#8201;178 (HR 2.833, 95% CI: 1.027&#8211;7.814), respectively. Among patients with stricturing disease phenotype, midLS and convLS identified patients with higher risk for clinical exacerbation [AUC 0.753 (95% CI: 0.564&#8211;0.942, <italic toggle="yes">p</italic>&#8201;=&#8201;0.029) <italic toggle="yes">versus</italic> 0.741 (95% CI: 0.544&#8211;0.938, <italic toggle="yes">p</italic>&#8201;=&#8201;0.037)], with ideal thresholds of midLS&#8201;&#10878;&#8201;160 (HR 3.774, 95% CI: 1.156&#8211;12.128) and convLS&#8201;&#10878;&#8201;435 (HR 2.792, 95% CI: 0.850&#8211;9.171), respectively. Among patients who have not been treated with biologics at baseline (<italic toggle="yes">n</italic>&#8201;=&#8201;32), midLS was the single only small-bowel segment to significantly identify those patients with a higher risk for future clinical exacerbation (AUC&#8201;=&#8201;0.744, 95% CI: 0.569&#8211;0.920, <italic toggle="yes">p</italic>&#8201;=&#8201;0.019).</p><fig position="float" id="fig3-17562848231188587" orientation="portrait"><label>Figure 3.</label><caption><p>Kaplan&#8211;Meier graph of survival without the predefined composite outcome (intestinal surgery, endoscopic dilation, CD-related admission, need for corticosteroids, or biological/immunomodulator treatment change) among patients with complicated disease phenotype, divided to patients with and without middle small-bowel segment Lewis score (midLS)&#8201;&#10878;&#8201;178.</p><p>CD, Crohn&#8217;s disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17562848231188587-fig3.jpg"/></fig><fig position="float" id="fig4-17562848231188587" orientation="portrait"><label>Figure 4.</label><caption><p>Kaplan&#8211;Meier graph of survival without the predefined composite outcome (intestinal surgery, endoscopic dilation, CD related admission, need for corticosteroids, or biological/immunomodulator treatment change) among patients with stricturing disease phenotype, divided to patients with and without middle small-bowel segment Lewis score (midLS)&#8201;&#10878;&#8201;160.</p><p>CD, Crohn&#8217;s disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17562848231188587-fig4.jpg"/></fig><p>We did not observe any of the examined MRE scores or the examined inflammatory biomarkers to well identify clinical exacerbation among the cohort population (AUC&#8201;&lt;&#8201;0.7) during the follow-up (<xref rid="table2-17562848231188587" ref-type="table">Table 2</xref>).</p></sec><sec sec-type="discussion" id="section14-17562848231188587"><title>Discussion</title><p>In this study, we aimed to explore long-term clinical outcomes, among patients with quiescent CD during an extended follow-up. We found midLS&#8201;&#10878;&#8201;135 to accurately identify future clinical exacerbation among these patients, overshadowing the other examined inflammatory biomarkers and MRE scores. To the best of our knowledge, this was the longest follow-up (median of almost 5&#8201;years) of patients with quiescent CD, undergoing VCE, to evaluate the prediction role of VCE Lewis score for future clinical exacerbation in this population.</p><p>Lewis score is a VCE scoring system to quantify small-bowel mucosal inflammation and stenosis of patients with CD.<sup>
<xref rid="bibr17-17562848231188587" ref-type="bibr">17</xref>
</sup> Mucosal inflammation is then classified into normal/clinically insignificant (&lt;135), mild (135&#8211;790), and moderate to severe (&#10878;790). Using the Lewis score system to diagnose CD (score&#8201;&gt;&#8201;135) had been proven to be very useful with higher rates of sensitivity (82.6&#8211;92%) and NPV (87.9&#8211;96%).<sup><xref rid="bibr18-17562848231188587" ref-type="bibr">18</xref><xref rid="bibr20-17562848231188587" ref-type="bibr"/>&#8211;<xref rid="bibr20-17562848231188587" ref-type="bibr">20</xref></sup> There was also a significant association between a higher Lewis score and the need for treatment escalation, intestinal resection, and hospital admission among newly diagnosed CD patients, within the first year after diagnosis.<sup>
<xref rid="bibr18-17562848231188587" ref-type="bibr">18</xref>
</sup> Our group had demonstrated that VCE-based monitoring of patients with quiescent CD was accurate, and that Lewis score cutoff&#8201;&#10878;&#8201;350 had the highest yield in predicting clinical flares (defined as &#916;CDAI&#8201;&gt;&#8201;70&#8201;points from baseline and CDAI&#8201;&gt;&#8201;150 or need for rescue treatment) during 24&#8201;months of follow-up.<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup> Recently, Nishilawwa <italic toggle="yes">et&#8239;al.</italic> had presented a Lewis score cutoff&#8201;&#10878;&#8201;270 as a predictor of CD-related emergency hospitalization, and clinical flares (defined by the need of treatment change/endoscopic intervention) within 2-year follow-up of CD patients with or without disease activity.<sup>
<xref rid="bibr10-17562848231188587" ref-type="bibr">10</xref>
</sup> They also showed that among those patients who had met that cutoff, treatment modification led to improved clinical outcomes during follow-up, compared with patients whose treatment had been unchanged.<sup>
<xref rid="bibr10-17562848231188587" ref-type="bibr">10</xref>
</sup> We demonstrated that VCE-based monitoring has well-identified patients with quiescent CD, who had a higher risk for future clinical exacerbation over an extended follow-up (median 5&#8201;years), independently of disease phenotype. To the best of our knowledge, this was the longest clinical follow-up of patients with quiescent CD who underwent baseline VCE.</p><p>VCE use among newly diagnosed patients with CD is highly recommended.<sup><xref rid="bibr1-17562848231188587" ref-type="bibr">1</xref>,<xref rid="bibr6-17562848231188587" ref-type="bibr">6</xref></sup> It allows us to visualize previously considered obscured segments of the small bowel, resulting in more accurate diagnosis and disease extent classification of patients with CD.<sup>
<xref rid="bibr21-17562848231188587" ref-type="bibr">21</xref>
</sup> Jejunal and/or ileal involvement of CD is associated with worse long-term clinical outcomes,<sup><xref rid="bibr22-17562848231188587" ref-type="bibr">22</xref><xref rid="bibr24-17562848231188587" ref-type="bibr"/><xref rid="bibr25-17562848231188587" ref-type="bibr"/>&#8211;<xref rid="bibr25-17562848231188587" ref-type="bibr">25</xref></sup> while ileal involvement is generally more difficult to treat, compared with colonic involvement.<sup>
<xref rid="bibr22-17562848231188587" ref-type="bibr">22</xref>
</sup> Thus, it is conceivable that midLS, which had been probably represented a significant part of the jejunal and ileal segments, was the most accurate predictor for future clinical exacerbation in patients with quiescent CD (AUC&#8201;=&#8201;0.767). Our findings were consistent with our previous research,<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup> in which Lewis score of the middle small-bowel segment has the highest AUC (0.79) compared to the Lewis score of either proximal (AUC&#8201;=&#8201;0.64) or distal (AUC&#8201;=&#8201;0.68) small-bowel segments, to predict clinical flares during 24-month follow-up. Lewis scores of both middle small-bowel segment and the conventional one were equal (AUC&#8201;=&#8201;0.79) in their accuracy to predict flares during 24-month follow-up.<sup>
<xref rid="bibr7-17562848231188587" ref-type="bibr">7</xref>
</sup> In this study, using a broader disease outcomes definition and an extended long-term follow-up (median 5&#8201;years), we found that midLS tended to better predict future clinical exacerbation compared with the conventional one (AUC 0.767 <italic toggle="yes">versus</italic> 0.734). Future prospective research with larger cohort size is of prime importance to further establish these findings, and to appropriately implement it in the real-life practice of patients with CD.</p><p>The Lewis score system divides the small bowel into three segments (i.e. proximal, middle, and distal) according to the transit time along the small bowel.<sup>
<xref rid="bibr26-17562848231188587" ref-type="bibr">26</xref>
</sup> Therefore, the anatomical extent of each segment may be influenced by several factors which have been previously found to hasten (e.g. prokinetics) or delay (e.g. aging, intestinal stenosis, diabetes) small-bowel transit time.<sup><xref rid="bibr27-17562848231188587" ref-type="bibr">27</xref>,<xref rid="bibr28-17562848231188587" ref-type="bibr">28</xref></sup> Yet, many reports in this field are conflicting, including those studies in which intra-individual transit time variations have been tested.<sup><xref rid="bibr27-17562848231188587" ref-type="bibr">27</xref>,<xref rid="bibr28-17562848231188587" ref-type="bibr">28</xref></sup> The patients in our cohort were exclusively consisted of CD patients, subsequently, all of them were prone to delayed small-bowel transit time.<sup>
<xref rid="bibr29-17562848231188587" ref-type="bibr">29</xref>
</sup> However, these patients were younger [median age of 29 (24&#8211;37)] than the age groups previously reported to have a delayed small-bowel transit time (65&#8211;75<sup>
<xref rid="bibr27-17562848231188587" ref-type="bibr">27</xref>
</sup>, &gt;75,<sup>
<xref rid="bibr27-17562848231188587" ref-type="bibr">27</xref>
</sup> and &gt;40<sup>
<xref rid="bibr29-17562848231188587" ref-type="bibr">29</xref>
</sup>&#8201;years old). Our findings were consistent even among patients of the stricturing disease phenotype group (<italic toggle="yes">n</italic>&#8201;=&#8201;26), as midLS still identified future clinical exacerbation in this population, although the small-bowel transit time may be deferred in patients with intestinal stenosis.<sup>
<xref rid="bibr27-17562848231188587" ref-type="bibr">27</xref>
</sup></p><p>Previously published studies have demonstrated the prime importance of biologics to reduce surgery rates among CD patients<sup><xref rid="bibr30-17562848231188587" ref-type="bibr">30</xref><xref rid="bibr32-17562848231188587" ref-type="bibr"/>&#8211;<xref rid="bibr32-17562848231188587" ref-type="bibr">32</xref></sup>; however, improvement in diagnostic tools and disease monitoring play an important role in dealing with CD as well<sup>
<xref rid="bibr32-17562848231188587" ref-type="bibr">32</xref>
</sup>. Biologics use among patients with inflammatory bowel disease (IBD) holds some disadvantages including immunogenicity, infectious complications, liver injury, neurological lesions, and skin manifestations,<sup>
<xref rid="bibr33-17562848231188587" ref-type="bibr">33</xref>
</sup> as well as biologics nonadherence which is quite common in this population. Subsequently, the potential beneficial effects of that group of medications in patients with IBD is limited.<sup>
<xref rid="bibr34-17562848231188587" ref-type="bibr">34</xref>
</sup> In this study, biologics had been more commonly used among patients who did not experience clinical exacerbation during follow-up, compared with those who did experience. Thus, we could not exclude a possible effect of their use on the study outcomes. However, among the patients without biologics at baseline, midLS well identified those patients with a higher risk for future clinical exacerbation among others. We believe that this finding may better guide an appropriate use of biologics, to improve disease control in this population.</p></sec><sec id="section15-17562848231188587"><title>Limitations</title><p>This study has several limitations. First, we could not use CDAI score changes as an outcome, due to unavailable data during the extended follow-up, but for the initial prospective follow-up (up to 2018). Instead, we have defined a primary composite outcome composed of broadened and stringent disease outcomes, which may further strengthen our findings. Second, we cannot exclude a possible bias whereby physicians of patients who had a high baseline Lewis score were more inclined to modify their treatment compared to patients with normal Lewis score. However, all patients had quiescent disease at the time they underwent VCE, and the median time between VCE and the primary composite outcome was 32.5 (IQR: 9.75&#8211;62.25) months [28.5 (10.25&#8211;73.25) months to treatment change], making it unlikely that VCE results solely in itself led to treatment modification, rather than clinical progression in a much later physician&#8217;s judgment. Third, we had a modest cohort size with a low event to variable ratio limiting us in performing multivariable analysis. However, it was a well-characterized cohort composed of patients with quiescent CD, enabling us to perform sensitivity analyses based on disease phenotype, and on a distinct group of patients without biologics at baseline. Moreover, a sample size of only 54 patients (26 and 28 patients in the midLS&#8201;&lt;&#8201;135 and midLS&#8201;&#10878;&#8201;135 groups, respectively) would have been appropriate to fulfill the statistical constraints of our findings (i.e. survival analysis in regard to midLS&#8201;&#10878;&#8201;135, at a significance level of 5% and a power of 80%). Finally, since patients with retained PC were excluded, generalizability of the study&#8217;s findings is limited. However, this study extends the prognostication scope of capsule endoscopy, whereby patients with retained PC as their first diagnostic step have been shown to have worse long-term outcomes (Ukashi, AJG<sup>
<xref rid="bibr13-17562848231188587" ref-type="bibr">13</xref>
</sup>), and this study shows that patients with confirmed patency who perform VCE can be further risk-stratified based on midLS inflammation.</p></sec><sec sec-type="conclusions" id="section16-17562848231188587"><title>Conclusion</title><p>In conclusion, to the best of our knowledge, this is the longest follow-up of patients with quiescent CD undergoing VCE. For the first time, we demonstrated that midLS is an accurate predictor for clinical exacerbation (median follow-up 5&#8201;years), among patients with CD, independently of disease phenotype. Thus, midLS may identify patients with higher risk for treatment failure, to guiding stricter monitoring and more rigorous management modification in this population.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Offir Ukashi <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17562848231188587-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-8601-6550" ext-link-type="uri">https://orcid.org/0000-0002-8601-6550</ext-link></p><p>Doron Yablecovitch <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17562848231188587-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-6191-9270" ext-link-type="uri">https://orcid.org/0000-0001-6191-9270</ext-link></p><p>Adi Lahat <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17562848231188587-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-1513-7280" ext-link-type="uri">https://orcid.org/0000-0003-1513-7280</ext-link></p><p>Uri Kopylov <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17562848231188587-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-7156-0588" ext-link-type="uri">https://orcid.org/0000-0002-7156-0588</ext-link></p></fn></fn-group><sec id="section17-17562848231188587"><title>Declarations</title><fn-group><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This study was carried out in accordance with the ethical guidelines of the Declaration of Helsinki. The study was approved by the Sheba Medical Center ethics committee. Approval was granted for Helsinki protocol SMC-13-0218. A written informed consent was obtained from all patients.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Offir Ukashi:</bold> Conceptualization; Data curation; Formal analysis; Methodology; Writing &#8211; original draft.</p><p><bold>Doron Yablecovitch:</bold> Data curation; Writing &#8211; review &amp; editing.</p><p><bold>Adi Lahat:</bold> Data curation; Writing &#8211; review &amp; editing.</p><p><bold>Limor Selinger:</bold> Data curation; Writing &#8211; review &amp; editing.</p><p><bold>Sandra Neuman:</bold> Data curation; Writing &#8211; review &amp; editing.</p><p><bold>Rami Eliakim:</bold> Data curation; Writing &#8211; review &amp; editing.</p><p><bold>Shomron Ben-Horin:</bold> Data curation; Writing &#8211; review &amp; editing.</p><p><bold>Uri Kopylov:</bold> Conceptualization; Data curation; Investigation; Methodology; Writing &#8211; original draft.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partially supported by a generous grant from the Leona M. and Harry B. Helmsley Charitable Trust and partially supported by Medtronic.</p></fn><fn fn-type="COI-statement"><p>Shomron Ben-Horin has received advisory board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, BMS, and Eli Lilly; holds stocks/options in Predicta Med, Evinature and Galmed; and received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, and Galmed. Uri Kopylov received speaker and consulting fees from Abbvie, BMS, Celtrion, Janssen, Medtronic, and Pfizerand Takeda and research support from Medtronic, Takeda, and Janssen. Rami Eliakim received consultant and speaker fees from Janssen, Abbvie, Takeda, and Medtronic. The remaining authors declare that they have no conflicts of interest.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> Not applicable.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bibr1-17562848231188587"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtenstein</surname><given-names>GR</given-names></name><name name-style="western"><surname>Loftus</surname><given-names>EV</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>KL</given-names></name></person-group>, <etal>et al</etal>. <article-title>ACG clinical guideline: management of Crohn&#8217;s disease in adults</article-title>. <source>Am J Gastroenterol</source><year>2018</year>; <volume>113</volume>: <fpage>481</fpage>&#8211;<lpage>517</lpage>.<pub-id pub-id-type="pmid">29610508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2018.27</pub-id></mixed-citation></ref><ref id="bibr2-17562848231188587"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <article-title>Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn&#8217;s disease</article-title>. <source>Therap Adv Gastroenterol</source><year>2021</year>; <volume>14</volume>: <fpage>17562848211016260</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17562848211016259</pub-id><pub-id pub-id-type="pmcid">PMC8193655</pub-id><pub-id pub-id-type="pmid">34178114</pub-id></mixed-citation></ref><ref id="bibr3-17562848231188587"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>. <article-title>Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn&#8217;s disease: a multicenter cohort study</article-title>. <source>BMC Gastroenterol</source><year>2022</year>; <volume>22</volume>: <fpage>229</fpage>.<pub-id pub-id-type="pmid">35538410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-022-02304-y</pub-id><pub-id pub-id-type="pmcid">PMC9088028</pub-id></mixed-citation></ref><ref id="bibr4-17562848231188587"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>D</given-names></name><name name-style="western"><surname>Ricciuto</surname><given-names>A</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD</article-title>. <source>Gastroenterology</source><year>2021</year>; <volume>160</volume>: <fpage>1570</fpage>&#8211;<lpage>1583</lpage>.<pub-id pub-id-type="pmid">33359090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.12.031</pub-id></mixed-citation></ref><ref id="bibr5-17562848231188587"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamamura</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Diagnostic yield of colon capsule endoscopy for Crohn&#8217;s disease lesions in the whole gastrointestinal tract</article-title>. <source>BMC Gastroenterol</source><year>2021</year>; <volume>21</volume>: <fpage>75</fpage>.<pub-id pub-id-type="pmid">33593297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-021-01657-0</pub-id><pub-id pub-id-type="pmcid">PMC7888071</pub-id></mixed-citation></ref><ref id="bibr6-17562848231188587"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sturm</surname><given-names>A</given-names></name><name name-style="western"><surname>Maaser</surname><given-names>C</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>ECCO-ESGAR guideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects</article-title>. <source>J Crohns Colitis</source><year>2019</year>; <volume>13</volume>: <fpage>273</fpage>&#8211;<lpage>284</lpage>.<pub-id pub-id-type="pmid">30137278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ecco-jcc/jjy114</pub-id></mixed-citation></ref><ref id="bibr7-17562848231188587"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Horin</surname><given-names>S</given-names></name><name name-style="western"><surname>Lahat</surname><given-names>A</given-names></name><name name-style="western"><surname>Amitai</surname><given-names>MM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn&#8217;s disease flare: a prospective cohort study</article-title>. <source>Lancet Gastroenterol Hepatol</source><year>2019</year>; <volume>4</volume>: <fpage>519</fpage>&#8211;<lpage>528</lpage>.<pub-id pub-id-type="pmid">31080097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(19)30088-3</pub-id></mixed-citation></ref><ref id="bibr8-17562848231188587"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picco</surname><given-names>MF</given-names></name><name name-style="western"><surname>Farraye</surname><given-names>FA.</given-names></name></person-group><article-title>Targeting mucosal healing in Crohn&#8217;s disease</article-title>. <source>Gastroenterol Hepatol (N Y)</source><year>2019</year>; <volume>15</volume>: <fpage>529</fpage>&#8211;<lpage>538</lpage>.<pub-id pub-id-type="pmid">31802977</pub-id><pub-id pub-id-type="pmcid">PMC6883736</pub-id></mixed-citation></ref><ref id="bibr9-17562848231188587"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petruzziello</surname><given-names>C</given-names></name><name name-style="western"><surname>Onali</surname><given-names>S</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>Wireless capsule endoscopy and proximal small bowel lesions in Crohn&#8217;s disease</article-title>. <source>World J Gastroenterol</source><year>2010</year>; <volume>16</volume>: <fpage>3299</fpage>&#8211;<lpage>3304</lpage>.<pub-id pub-id-type="pmid">20614486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v16.i26.3299</pub-id><pub-id pub-id-type="pmcid">PMC2900722</pub-id></mixed-citation></ref><ref id="bibr10-17562848231188587"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamamura</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <article-title>Lewis score on capsule endoscopy can predict the prognosis in patients with small bowel lesions of Crohn&#8217;s disease</article-title>. <source>J Gastroenterol Hepatol</source><year>2021</year>; <volume>36</volume>: <fpage>1851</fpage>&#8211;<lpage>1858</lpage>.<pub-id pub-id-type="pmid">33283324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.15366</pub-id></mixed-citation></ref><ref id="bibr11-17562848231188587"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niv</surname><given-names>Y.</given-names></name></person-group><article-title>Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn&#8217;s disease: a systematic review and meta-analysis</article-title>. <source>Eur J Gastroenterol Hepatol</source><year>2017</year>; <volume>29</volume>: <fpage>844</fpage>&#8211;<lpage>848</lpage>.<pub-id pub-id-type="pmid">28410352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0000000000000881</pub-id></mixed-citation></ref><ref id="bibr12-17562848231188587"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#246;mmele</surname><given-names>C</given-names></name><name name-style="western"><surname>Brueckner</surname><given-names>J</given-names></name><name name-style="western"><surname>Messmann</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Clinical experience with the PillCam patency capsule prior to video capsule endoscopy: a real-world experience</article-title>. <source>Gastroenterol Res Pract</source><year>2016</year>; <volume>2016</volume>: <fpage>9657053</fpage>.<pub-id pub-id-type="pmid">26880902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/9657053</pub-id><pub-id pub-id-type="pmcid">PMC4736905</pub-id></mixed-citation></ref><ref id="bibr13-17562848231188587"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ukashi</surname><given-names>O</given-names></name><name name-style="western"><surname>Kopylov</surname><given-names>U</given-names></name><name name-style="western"><surname>Ungar</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>. <article-title>Patency capsule: a novel independent predictor for long-term outcomes among patients with quiescent Crohn&#8217;s disease</article-title>. <source>Am J Gastroenterol</source><year>2023</year>; <volume>118</volume>: <fpage>1019</fpage>&#8211;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">36563317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000002118</pub-id></mixed-citation></ref><ref id="bibr14-17562848231188587"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hordonneau</surname><given-names>C</given-names></name><name name-style="western"><surname>Buisson</surname><given-names>A</given-names></name><name name-style="western"><surname>Scanzi</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn&#8217;s disease: validation of quantitative index of activity</article-title>. <source>Am J Gastroenterol</source><year>2014</year>; <volume>109</volume>: <fpage>89</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">24247212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2013.385</pub-id></mixed-citation></ref><ref id="bibr15-17562848231188587"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ord&#225;s</surname><given-names>I</given-names></name><name name-style="western"><surname>Rimola</surname><given-names>J</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn&#8217;s disease</article-title>. <source>Gastroenterology</source><year>2014</year>; <volume>146</volume>: 374&#8211;382.e1.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.10.055</pub-id><pub-id pub-id-type="pmid">24177375</pub-id></mixed-citation></ref><ref id="bibr16-17562848231188587"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pariente</surname><given-names>B</given-names></name><name name-style="western"><surname>Mary</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Danese</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Development of the L&#233;mann index to assess digestive tract damage in patients with Crohn&#8217;s disease</article-title>. <source>Gastroenterology</source><year>2015</year>; <volume>148</volume>: 52&#8211;63.e3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.09.015</pub-id><pub-id pub-id-type="pmid">25241327</pub-id></mixed-citation></ref><ref id="bibr17-17562848231188587"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gralnek</surname><given-names>IM</given-names></name><name name-style="western"><surname>Defranchis</surname><given-names>R</given-names></name><name name-style="western"><surname>Seidman</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <article-title>Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change</article-title>. <source>Aliment Pharmacol Ther</source><year>2008</year>; <volume>27</volume>: <fpage>146</fpage>&#8211;<lpage>154</lpage>.<pub-id pub-id-type="pmid">17956598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2036.2007.03556.x</pub-id></mixed-citation></ref><ref id="bibr18-17562848231188587"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>AL</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Lewis score: a useful tool for diagnosis and prognosis in Crohn&#8217;s disease</article-title>. <source>Rev Esp Enferm Dig</source><year>2020</year>; <volume>112</volume>: <fpage>121</fpage>&#8211;<lpage>126</lpage>.<pub-id pub-id-type="pmid">31960694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17235/reed.2020.6434/2019</pub-id></mixed-citation></ref><ref id="bibr19-17562848231188587"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>B</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rebelo</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <article-title>Lewis score: a useful clinical tool for patients with suspected Crohn&#8217;s disease submitted to capsule endoscopy</article-title>. <source>J Crohns Colitis</source><year>2012</year>; <volume>6</volume>: <fpage>692</fpage>&#8211;<lpage>697</lpage>.<pub-id pub-id-type="pmid">22398099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crohns.2011.12.002</pub-id></mixed-citation></ref><ref id="bibr20-17562848231188587"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro</surname><given-names>S</given-names></name><name name-style="western"><surname>Boal Carvalho</surname><given-names>P</given-names></name><name name-style="western"><surname>Dias de Castro</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>. <article-title>Capsule endoscopy: diagnostic accuracy of Lewis score in patients with suspected Crohn&#8217;s disease</article-title>. <source>Inflamm Bowel Dis</source><year>2015</year>; <volume>21</volume>: <fpage>2241</fpage>&#8211;<lpage>2246</lpage>.<pub-id pub-id-type="pmid">26197449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000000517</pub-id></mixed-citation></ref><ref id="bibr21-17562848231188587"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopylov</surname><given-names>U</given-names></name><name name-style="western"><surname>Seidman</surname><given-names>EG.</given-names></name></person-group><article-title>Role of capsule endoscopy in inflammatory bowel disease</article-title>. <source>World J Gastroenterol</source><year>2014</year>; <volume>20</volume>: <fpage>1155</fpage>&#8211;<lpage>1164</lpage>.<pub-id pub-id-type="pmid">24574792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v20.i5.1155</pub-id><pub-id pub-id-type="pmcid">PMC3921500</pub-id></mixed-citation></ref><ref id="bibr22-17562848231188587"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atreya</surname><given-names>R</given-names></name><name name-style="western"><surname>Bojarski</surname><given-names>C</given-names></name><name name-style="western"><surname>K&#252;hl</surname><given-names>AA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Ileal and colonic Crohn&#8217;s disease: does location makes a difference in therapy efficacy?</article-title><source>Curr Res Pharmacol drug Discov</source><year>2022</year>; <volume>3</volume>: <fpage>100097</fpage>.<pub-id pub-id-type="pmid">35345820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crphar.2022.100097</pub-id><pub-id pub-id-type="pmcid">PMC8956925</pub-id></mixed-citation></ref><ref id="bibr23-17562848231188587"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>OZ</given-names></name><name name-style="western"><surname>Han</surname><given-names>DS</given-names></name><name name-style="western"><surname>Park</surname><given-names>CH</given-names></name></person-group>, <etal>et al</etal>. <article-title>The clinical characteristics and prognosis of Crohn&#8217;s disease in Korean patients showing proximal small bowel involvement: results from the CONNECT study</article-title>. <source>Gut Liver</source><year>2018</year>; <volume>12</volume>: <fpage>67</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">28798284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5009/gnl16500</pub-id><pub-id pub-id-type="pmcid">PMC5753686</pub-id></mixed-citation></ref><ref id="bibr24-17562848231188587"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Park</surname><given-names>YL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Development of a novel predictive model for the clinical course of Crohn&#8217;s disease: results from the CONNECT study</article-title>. <source>Inflamm Bowel Dis</source><year>2017</year>; <volume>23</volume>: <fpage>1071</fpage>&#8211;<lpage>1079</lpage>.<pub-id pub-id-type="pmid">28410345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000001106</pub-id></mixed-citation></ref><ref id="bibr25-17562848231188587"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louis</surname><given-names>E</given-names></name><name name-style="western"><surname>Collard</surname><given-names>A</given-names></name><name name-style="western"><surname>Oger</surname><given-names>AF</given-names></name></person-group>, <etal>et al</etal>. <article-title>Behaviour of Crohn&#8217;s disease according to the Vienna classification: changing pattern over the course of the disease</article-title>. <source>Gut</source><year>2001</year>; <volume>49</volume>: <fpage>777</fpage>&#8211;<lpage>782</lpage>.<pub-id pub-id-type="pmid">11709511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.49.6.777</pub-id><pub-id pub-id-type="pmcid">PMC1728556</pub-id></mixed-citation></ref><ref id="bibr26-17562848231188587"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>B</given-names></name><name name-style="western"><surname>Margalit-Yehuda</surname><given-names>R</given-names></name><name name-style="western"><surname>Gatt</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. <article-title>Scoring systems in clinical small-bowel capsule endoscopy: all you need to know!</article-title><source>Endosc Int Open</source><year>2021</year>; <volume>9</volume>: <fpage>E802</fpage>&#8211;<lpage>E823</lpage>.<pub-id pub-id-type="pmid">34079861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1372-4051</pub-id><pub-id pub-id-type="pmcid">PMC8159625</pub-id></mixed-citation></ref><ref id="bibr27-17562848231188587"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tominaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>H</given-names></name><name name-style="western"><surname>Yokomichi</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>. <article-title>Variation in small bowel transit time on capsule endoscopy</article-title>. <source>Ann Transl Med</source><year>2020</year>; <volume>8</volume>: <fpage>348</fpage>.<pub-id pub-id-type="pmid">32355792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2020.02.40</pub-id><pub-id pub-id-type="pmcid">PMC7186741</pub-id></mixed-citation></ref><ref id="bibr28-17562848231188587"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakurai</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimori</surname><given-names>S</given-names></name><name name-style="western"><surname>Hayashida</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Repeatability of small bowel transit time in capsule endoscopy in healthy subjects</article-title>. <source>Biomed Mater Eng</source><year>2018</year>; <volume>29</volume>: <fpage>839</fpage>&#8211;<lpage>848</lpage>.<pub-id pub-id-type="pmid">30282338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/BME-181027</pub-id></mixed-citation></ref><ref id="bibr29-17562848231188587"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fireman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kopelman</surname><given-names>Y</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. <article-title>Age and indication for referral to capsule endoscopy significantly affect small bowel transit times: the given database</article-title>. <source>Dig Dis Sci</source><year>2007</year>; <volume>52</volume>: <fpage>2884</fpage>&#8211;<lpage>2887</lpage>.<pub-id pub-id-type="pmid">17406814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-007-9789-1</pub-id></mixed-citation></ref><ref id="bibr30-17562848231188587"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurowski</surname><given-names>JA</given-names></name><name name-style="western"><surname>Milinovich</surname><given-names>A</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>Differences in biologic utilization and surgery rates in pediatric and adult Crohn&#8217;s disease: results from a large electronic medical record-derived cohort</article-title>. <source>Inflamm Bowel Dis</source><year>2021</year>; <volume>27</volume>: <fpage>1035</fpage>&#8211;<lpage>1044</lpage>.<pub-id pub-id-type="pmid">32914165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izaa239</pub-id></mixed-citation></ref><ref id="bibr31-17562848231188587"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name><name name-style="western"><surname>Oussalah</surname><given-names>A</given-names></name><name name-style="western"><surname>Williet</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <article-title>Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn&#8217;s disease</article-title>. <source>Gut</source><year>2011</year>; <volume>60</volume>: <fpage>930</fpage>&#8211;<lpage>936</lpage>.<pub-id pub-id-type="pmid">21228429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2010.227884</pub-id></mixed-citation></ref><ref id="bibr32-17562848231188587"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dittrich</surname><given-names>AE</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>RT</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. <article-title>Incidence rates for surgery in Crohn&#8217;s disease have decreased: a population-based time-trend analysis</article-title>. <source>Inflamm Bowel Dis</source><year>2020</year>; <volume>26</volume>: <fpage>1909</fpage>&#8211;<lpage>1916</lpage>.<pub-id pub-id-type="pmid">31895949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izz315</pub-id></mixed-citation></ref><ref id="bibr33-17562848231188587"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Haens</surname><given-names>G.</given-names></name></person-group><article-title>Risks and benefits of biologic therapy for inflammatory bowel diseases</article-title>. <source>Gut</source><year>2007</year>; <volume>56</volume>: <fpage>725</fpage>&#8211;<lpage>732</lpage>.<pub-id pub-id-type="pmid">17440187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2006.103564</pub-id><pub-id pub-id-type="pmcid">PMC1942157</pub-id></mixed-citation></ref><ref id="bibr34-17562848231188587"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wentworth</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Buerlein</surname><given-names>RCD</given-names></name><name name-style="western"><surname>Tuskey</surname><given-names>AG</given-names></name></person-group>, <etal>et al</etal>. <article-title>Nonadherence to biologic therapies in inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source><year>2018</year>; <volume>24</volume>: <fpage>2053</fpage>&#8211;<lpage>2061</lpage>.<pub-id pub-id-type="pmid">29668917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izy102</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>